Operating from its headquarters in the UK, with subsidiaries in the USA, Canada and Spain, Deltex Medical manufactures and markets the TrueVue™ system featuring Oesophageal Doppler Monitoring (ODM™) technology.
Deltex Medical’s Oesophageal Doppler Monitor (ODM+) changes the way clinicians can care for patients having major surgery or in intensive care. ODM is the only technology to measure blood flow continuously in the central circulation; it is highly sensitive to changes in flow and measures them immediately and accurately. ODM is simple to use and enables Clinicians to intervene quickly and safely, based on small changes in circulating blood volume and so avoid the dangers of reduced oxygen delivery.
ODM guided intraoperative fluid management (IOFM) is a cornerstone of Enhanced Recovery; delivering better quality, more cost effective care. It means patients recover from their surgery faster, leave hospital sooner and in better health than they otherwise would do. Having established a substantial high quality evidence base supporting wide-scale use of its products on both clinical and economic grounds, Deltex Medical is working with leading hospitals around the world to introduce ODM-guided fluid management into routine use.
The Group will shortly launch a new, next generation monitor which will make the use of the ODM technology more intuitive and provide augmented data on the status of each patient. Deltex Medical’s engineers and scientists carried out successful research in conjunction with the UK’s National Physical Laboratory (“NPL”), which has enabled the Group’s ‘gold standard’ ODM technology to be extended and developed so that it can be used completely non-invasively. This will significantly expand the application of Deltex Medical’s technology to non-sedated patients.